Jade Biosciences, Inc.
JBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeJade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. With a market capitalization of $927.9M, it sits in small-cap territory. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
Market Cap
$927.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-5.48
EPS (TTM)
$-1.92
EPS (Fwd)
$-2.66
ROE
—
ROA
—
Cash
$461.2M
Total Debt
$1.4M
Free CF
—
52W Change
43.2%
Annual Financials
Cash vs Debt
Where JBIO stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, JBIO finished 27.84% below its 150-day moving average ($19.40) and 23.33% below its 200-day moving average ($18.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is JBIO overbought or oversold?
At the October 13, 2026 close, JBIO's RSI(14) was 24.7, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $461.2M in cash and $1.4M in debt, JBIO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Jade Biosciences, Inc.'s trajectory.